MX2019003726A - Metodos para tratar fibroides uterinos y endometriosis. - Google Patents

Metodos para tratar fibroides uterinos y endometriosis.

Info

Publication number
MX2019003726A
MX2019003726A MX2019003726A MX2019003726A MX2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A
Authority
MX
Mexico
Prior art keywords
subject
methods
endometriosis
reducing
uterine fibroids
Prior art date
Application number
MX2019003726A
Other languages
English (en)
Spanish (es)
Inventor
Hibberd Mark
Reddy Rajasekhar Vijaykumar
Mark Johnson Brendan
Seely Lynn
N Mudd Paul Jr
Wollowitz Susan
Tanimoto Masataka
Vasant Sukhatme Mayukh
Original Assignee
Myovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019003726(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myovant Sciences Gmbh filed Critical Myovant Sciences Gmbh
Publication of MX2019003726A publication Critical patent/MX2019003726A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
MX2019003726A 2016-09-30 2017-09-29 Metodos para tratar fibroides uterinos y endometriosis. MX2019003726A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662402034P 2016-09-30 2016-09-30
US201662402055P 2016-09-30 2016-09-30
US201662402150P 2016-09-30 2016-09-30
US201762492839P 2017-05-01 2017-05-01
US201762528409P 2017-07-03 2017-07-03
PCT/EP2017/074907 WO2018060501A2 (en) 2016-09-30 2017-09-29 Methods of treating uterine fibroids and endometriosis

Publications (1)

Publication Number Publication Date
MX2019003726A true MX2019003726A (es) 2019-09-26

Family

ID=60915460

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003726A MX2019003726A (es) 2016-09-30 2017-09-29 Metodos para tratar fibroides uterinos y endometriosis.

Country Status (24)

Country Link
US (4) US11033551B2 (enExample)
EP (2) EP4094766B1 (enExample)
JP (1) JP7043503B2 (enExample)
CN (1) CN110312512B (enExample)
AU (2) AU2017336363B2 (enExample)
BR (1) BR112019006227A2 (enExample)
CA (1) CA3038879A1 (enExample)
CY (1) CY1125254T1 (enExample)
DK (1) DK3518933T4 (enExample)
ES (2) ES2912929T5 (enExample)
FI (1) FI3518933T4 (enExample)
HR (1) HRP20220708T4 (enExample)
HU (2) HUE072130T2 (enExample)
IL (2) IL300580B2 (enExample)
LT (1) LT3518933T (enExample)
MD (1) MD3518933T4 (enExample)
MX (1) MX2019003726A (enExample)
NZ (1) NZ752916A (enExample)
PL (2) PL4094766T3 (enExample)
PT (1) PT3518933T (enExample)
RS (1) RS63300B2 (enExample)
SI (1) SI3518933T2 (enExample)
SM (1) SMT202200254T1 (enExample)
WO (1) WO2018060501A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3518932T3 (da) 2016-09-30 2025-01-27 Takeda Pharmaceuticals Co Behandling af prostatacancer
SMT202200254T1 (it) 2016-09-30 2022-07-21 Takeda Pharmaceuticals Co Metodi di trattamento di fibromi uterini ed endometriosi
US11759464B2 (en) 2017-06-05 2023-09-19 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
EP3634418A1 (en) 2017-06-05 2020-04-15 ObsEva S.A. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
AU2018419533A1 (en) * 2018-04-19 2020-11-12 Abbvie Inc. Methods of treating heavy menstrual bleeding
WO2020089190A2 (en) * 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
RU2711658C1 (ru) * 2019-04-16 2020-01-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения наружного генитального эндометриоза
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
KR20220061120A (ko) * 2019-08-08 2022-05-12 옵스에파 에스에이 에스트로겐-의존성 장애 치료용 조성물 및 방법
JP7713934B2 (ja) * 2019-10-10 2025-07-28 スミトモ ファーマ スウィッツァーランド ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶溶媒和形
WO2021069711A1 (en) * 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea
WO2021168040A1 (en) * 2020-02-19 2021-08-26 Aspira Women's Health Inc. Compositions for endometriosis assessment having improved specificity
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
MX2022015003A (es) * 2020-05-29 2023-03-03 Myovant Sciences Gmbh Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina.
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
CN118451082A (zh) 2021-10-18 2024-08-06 住友制药瑞士有限公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-N'-甲氧基脲的乙醇溶剂化物的结晶形式
CN117069735A (zh) * 2022-05-10 2023-11-17 北京海美源医药科技有限公司 一种高效合成瑞卢戈利的方法和其应用
WO2024015934A2 (en) * 2022-07-13 2024-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of diagnostic screening and early detection of adenomyosis
TW202428262A (zh) * 2022-11-09 2024-07-16 美商坦帕斯醫療公司 三唑酮化合物及其用途
WO2025106820A1 (en) * 2023-11-16 2025-05-22 University Of South Florida Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US402034A (en) 1889-04-23 Dumping-wagon
US402055A (en) 1889-04-23 Water-motor
US492839A (en) 1893-03-07 Key for brake-shoes
US528409A (en) 1894-10-30 Denis ahern
US402150A (en) 1889-04-30 Broadcast seed-sower
FR2512732A1 (fr) 1981-09-14 1983-03-18 Raffinage Cie Francaise Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
ECSP961635A (es) 1996-01-11 1997-06-27 Desprendimiento controlado de esteroides del recubrimiento de azucar
ECSP971998A (es) 1997-01-15 1998-04-07 Desprendimiento controlado de esteroides del recubrimiento de azucar
DE19815060A1 (de) 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6297379B1 (en) 1999-03-24 2001-10-02 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
US6849738B2 (en) 2000-02-29 2005-02-01 Takeda Chemical Industries, Ltd. Processes for the production of thienopyrimidine derivatives
US7569570B2 (en) 2002-01-30 2009-08-04 Takeda Pharmaceutical Company Limited Thienopyrimidines, process for preparing the same and use thereof
ZA200506611B (en) 2003-01-29 2006-12-27 Takeda Pharmaceutical Thienopyrimidine compounds and use thereof
WO2005007165A1 (en) 2003-07-07 2005-01-27 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20090048273A1 (en) 2005-07-22 2009-02-19 Takeda Pharmaceutical Company Limited Premature ovulation preventive agent
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
ES2534573T3 (es) 2007-04-06 2015-04-24 Neurocrine Biosciences, Inc. Antagonistas del receptor de la hormona liberadora de gonadotropina y métodos relacionados con los mismos
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
JPWO2010026993A1 (ja) 2008-09-03 2012-02-02 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
KR101731008B1 (ko) 2010-06-16 2017-04-27 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
JP2012077020A (ja) 2010-09-30 2012-04-19 Mochida Pharmaceut Co Ltd ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
SMT202200255T1 (it) 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
IL241595B2 (en) * 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
FI4233847T3 (fi) 2015-02-26 2024-09-24 Takeda Pharmaceuticals Co Metoksiureajohdannaista ja mannitolihiukkasia käsittävä tabletti
CA3002791A1 (en) 2015-09-01 2017-03-09 Abbvie Inc. Methods of administering elagolix
DK3518932T3 (da) 2016-09-30 2025-01-27 Takeda Pharmaceuticals Co Behandling af prostatacancer
SMT202200254T1 (it) 2016-09-30 2022-07-21 Takeda Pharmaceuticals Co Metodi di trattamento di fibromi uterini ed endometriosi
EP3634418A1 (en) 2017-06-05 2020-04-15 ObsEva S.A. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
JP7713934B2 (ja) 2019-10-10 2025-07-28 スミトモ ファーマ スウィッツァーランド ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶溶媒和形
WO2021069711A1 (en) 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea
MX2022015003A (es) 2020-05-29 2023-03-03 Myovant Sciences Gmbh Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina.
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
CN118451082A (zh) 2021-10-18 2024-08-06 住友制药瑞士有限公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-N'-甲氧基脲的乙醇溶剂化物的结晶形式

Also Published As

Publication number Publication date
ES2912929T5 (en) 2025-05-09
AU2022241582B2 (en) 2024-06-13
SI3518933T2 (sl) 2025-05-30
EP3518933A2 (en) 2019-08-07
IL265700B1 (en) 2023-03-01
SI3518933T1 (sl) 2022-06-30
US20220370462A1 (en) 2022-11-24
AU2017336363A1 (en) 2019-05-16
WO2018060501A3 (en) 2018-05-11
PL4094766T3 (pl) 2025-07-28
EP4094766B1 (en) 2025-04-02
IL300580B1 (en) 2025-07-01
MD3518933T2 (ro) 2022-07-31
US11793812B2 (en) 2023-10-24
FI3518933T4 (fi) 2025-05-14
HUE072130T2 (hu) 2025-10-28
PT3518933T (pt) 2022-05-10
EP3518933B1 (en) 2022-03-16
CN110312512A (zh) 2019-10-08
JP7043503B2 (ja) 2022-03-29
ES2912929T3 (es) 2022-05-30
CA3038879A1 (en) 2018-04-05
HRP20220708T1 (hr) 2022-07-22
US11033551B2 (en) 2021-06-15
CY1125254T1 (el) 2024-02-16
AU2022241582A1 (en) 2022-10-27
IL265700B2 (en) 2023-07-01
SMT202200254T1 (it) 2022-07-21
CN110312512B (zh) 2023-05-09
RS63300B2 (sr) 2025-05-30
IL300580B2 (en) 2025-11-01
AU2022241582C1 (en) 2024-11-28
MD3518933T4 (ro) 2025-10-31
AU2017336363B2 (en) 2022-08-04
PL3518933T5 (pl) 2025-05-05
EP4094766A1 (en) 2022-11-30
IL300580A (en) 2023-04-01
RS63300B1 (sr) 2022-07-29
DK3518933T4 (da) 2025-04-22
BR112019006227A2 (pt) 2019-06-18
JP2019529575A (ja) 2019-10-17
LT3518933T (lt) 2022-06-10
US11957684B2 (en) 2024-04-16
EP3518933B2 (en) 2025-02-26
IL265700A (en) 2019-05-30
ES3018413T3 (es) 2025-05-16
DK3518933T3 (da) 2022-05-30
US20240165118A1 (en) 2024-05-23
HRP20220708T4 (hr) 2025-04-25
WO2018060501A2 (en) 2018-04-05
US20190262346A1 (en) 2019-08-29
PL3518933T3 (pl) 2022-06-20
US20210401841A1 (en) 2021-12-30
HUE059101T2 (hu) 2022-10-28
NZ752916A (en) 2022-09-30

Similar Documents

Publication Publication Date Title
MX2019003726A (es) Metodos para tratar fibroides uterinos y endometriosis.
Chen et al. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl) phenyl) amino) pyrimidin-2-yl) amino)-4-methoxy-2-(4-methyl-1, 4-diazepan-1-yl) phenyl) acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC
MX2023001468A (es) Tratamiento de cancer de prostata.
NZ745957A (en) Heterocyclic amides useful as protein modulators
MX344580B (es) Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa.
EP4223298A3 (en) Compositions for use in treating heavy menstrual bleeding
NZ708563A (en) Treatment of cancers using pi3 kinase isoform modulators
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
JP2013540823A5 (enExample)
MY203694A (en) Sustained release dosage forms for a jak1 inhibitor
PH12021551290A1 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
EA201791361A1 (ru) Терапия антагонистом рецепторов окситоцина в лютеиновую фазу для имплантации и беременности у женщин, проходящих процедуры вспомогательных репродуктивных технологий
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
BR112018075206A2 (pt) tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
MX2019014482A (es) Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación.
NZ757929A (en) Benzoazepine analogs as inhibiting agents for bruton’s tyrosine kinase
IN2014DN08604A (enExample)
MX2015002005A (es) Combinacion de inhibidor de p13k e inhibidor de c-met.
PE20210096A1 (es) Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
PH12017502100A1 (en) Selective progesterone receptor modulator (sprm) regimen
MX389041B (es) Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos.
EA201990857A1 (ru) Способы лечения миомы матки и эндометриоза
MY188267A (en) Progesterone receptor antagonist dosage form
MA46362B1 (fr) Méthodes de traitement des fibromes utérins et de l'endométriose
EA201990057A1 (ru) Схемы применения антагониста окситоцина для содействия имплантации эмбриона и предотвращения выкидыша